Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Xediton Pharmaceuticals
October 28, 2020 02:00 ET | Quantum Genomics
Quantum Genomics to receive up to $11.35 million in upfront and milestone payments plus double-digit royalties on sales Xediton Pharmaceuticals to receive an exclusive license to develop and...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Qilu Pharmaceutical
October 19, 2020 02:00 ET | Quantum Genomics
Quantum Genomics to receive up to $50 million in upfront and milestone payments plus double-digit royalties on sales Qilu Pharmaceutical to receive an exclusive license to develop and commercialize...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Enters into Exclusive Licensing and Collaboration Agreement with Orient EuroPharma (OEP)
September 22, 2020 12:00 ET | Quantum Genomics
Quantum Genomics to receive up to $19 million in upfront and milestone payments plus double-digit royalties on sales OEP to receive an exclusive license to develop and commercialize firibastat for...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Enrolls First Patient in Its Pivotal Phase III FRESH Trial of Firibastat in Difficult-to-treat and Resistant Hypertension
July 13, 2020 02:00 ET | Quantum Genomics
PARIS and NEW YORK, July 13, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Announces Interim Analysis from Study of Firibastat in Renal Failure Patients
May 06, 2020 12:00 ET | Quantum Genomics
PARIS and NEW YORK, May 06, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that directly...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Provides Update on the Impact of the COVID-19 Health Crisis on Clinical Research Activities
April 07, 2020 12:00 ET | Quantum Genomics
PARIS and NEW YORK, April 07, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC), a biopharmaceutical company specializing in developing a new drug class that...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Secured New Financing, Published its Financial Statements for Fiscal Year 2019 and Provides 2019 Highlights
March 31, 2020 09:52 ET | Quantum Genomics
Despite the current public health crisis and any financial consequences it may have, the fact that Quantum Genomics has secured new financing confirms that investors remain confident in its outlook....
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Appoints Benoît Gueugnon as Vice President of Finance
January 28, 2020 01:30 ET | Quantum Genomics
PARIS and NEW YORK, Jan. 28, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC, OTCQX - QNNTF), a biopharmaceutical company specializing in developing a new drug...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics to Present at the Gordon Research Conference 2020 Dedicated to the Renin Angiotensin Aldosterone System
January 15, 2020 12:00 ET | Quantum Genomics
PARIS and NEW YORK, Jan. 15, 2020 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC, OTCQX - QNNTF), a biopharmaceutical company specializing in developing a new drug...
Logo_Quantum_Genomics-iloveimg-resized.png
Quantum Genomics Initiates its Pivotal Phase III FRESH Trial in Difficult-to-Treat and Resistant Hypertension
December 19, 2019 12:00 ET | Quantum Genomics
PARIS and NEW YORK, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC, OTCQX - QNNTF), a biopharmaceutical company specializing in developing a new drug...